A histone H1-binding-aptide-based apoptosis imaging probe for monitoring tumor responses to cancer therapy

Yonghyun Lee; Sunghyun Kim; Daejin Kim; Sangyong Jon

doi:10.1039/c6md00696e

A histone H1-binding-aptide-based apoptosis imaging probe for monitoring tumor responses to cancer therapy

Yonghyun Lee, Sunghyun Kim, Daejin Kim, Sangyong Jon

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Here we report the feasibility of using a high-affinity histone H1-binding peptide as a potential molecular apoptosis imaging probe. The Cy5.5-labeled peptide showed high selectivity for drug-treated apoptotic tumors compared with non-apoptotic tumors in various in vivo settings, enabling detection of tumor responses to both docetaxel chemotherapy and Herceptin antibody therapy as early as 12 hours after treatment with a high signal-to-background ratio, even at extremely low doses.

Original language	English
Pages (from-to)	390-393
Number of pages	4
Journal	MedChemComm
Volume	8
Issue number	2
DOIs	https://doi.org/10.1039/c6md00696e
State	Published - 2017

Bibliographical note

Funding Information:
This work was supported by the Global Research Laboratory grant (2015045887) and the Radiation Technology R&D program (2014033231) through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning.

Publisher Copyright:
© The Royal Society of Chemistry.

Access to Document

10.1039/c6md00696e

Cite this

@article{4ee27d91317347f1a3e42076372d52ac,

title = "A histone H1-binding-aptide-based apoptosis imaging probe for monitoring tumor responses to cancer therapy",

abstract = "Here we report the feasibility of using a high-affinity histone H1-binding peptide as a potential molecular apoptosis imaging probe. The Cy5.5-labeled peptide showed high selectivity for drug-treated apoptotic tumors compared with non-apoptotic tumors in various in vivo settings, enabling detection of tumor responses to both docetaxel chemotherapy and Herceptin antibody therapy as early as 12 hours after treatment with a high signal-to-background ratio, even at extremely low doses.",

author = "Yonghyun Lee and Sunghyun Kim and Daejin Kim and Sangyong Jon",

note = "Funding Information: This work was supported by the Global Research Laboratory grant (2015045887) and the Radiation Technology R\&D program (2014033231) through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT \& Future Planning. Publisher Copyright: {\textcopyright} The Royal Society of Chemistry.",

year = "2017",

doi = "10.1039/c6md00696e",

language = "English",

volume = "8",

pages = "390--393",

journal = "MedChemComm",

issn = "2040-2503",

publisher = "Royal Society of Chemistry",

number = "2",

}

TY - JOUR

T1 - A histone H1-binding-aptide-based apoptosis imaging probe for monitoring tumor responses to cancer therapy

AU - Lee, Yonghyun

AU - Kim, Sunghyun

AU - Kim, Daejin

AU - Jon, Sangyong

N1 - Funding Information: This work was supported by the Global Research Laboratory grant (2015045887) and the Radiation Technology R&D program (2014033231) through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning. Publisher Copyright: © The Royal Society of Chemistry.

PY - 2017

Y1 - 2017

N2 - Here we report the feasibility of using a high-affinity histone H1-binding peptide as a potential molecular apoptosis imaging probe. The Cy5.5-labeled peptide showed high selectivity for drug-treated apoptotic tumors compared with non-apoptotic tumors in various in vivo settings, enabling detection of tumor responses to both docetaxel chemotherapy and Herceptin antibody therapy as early as 12 hours after treatment with a high signal-to-background ratio, even at extremely low doses.

AB - Here we report the feasibility of using a high-affinity histone H1-binding peptide as a potential molecular apoptosis imaging probe. The Cy5.5-labeled peptide showed high selectivity for drug-treated apoptotic tumors compared with non-apoptotic tumors in various in vivo settings, enabling detection of tumor responses to both docetaxel chemotherapy and Herceptin antibody therapy as early as 12 hours after treatment with a high signal-to-background ratio, even at extremely low doses.

UR - https://www.scopus.com/pages/publications/85013829961

U2 - 10.1039/c6md00696e

DO - 10.1039/c6md00696e

M3 - Article

AN - SCOPUS:85013829961

SN - 2040-2503

VL - 8

SP - 390

EP - 393

JO - MedChemComm

JF - MedChemComm

IS - 2

ER -

A histone H1-binding-aptide-based apoptosis imaging probe for monitoring tumor responses to cancer therapy

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this